Glomerulosclerosis, Focal Segmental
Nephrology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Vertex PharmaceuticalsVX-147
GenomicsBiosampling
Clinical Trials (2)
Total enrollment: 516 patients across 2 trials
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Start: Jun 2020Est. completion: Dec 202116 patients
Phase 2Completed
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
Start: Apr 2018Est. completion: Mar 2033500 patients
N/ARecruiting
Related Jobs in Nephrology
Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery
AstraZeneca
Sweden - Gothenburg
6d ago
Director, Strategy & Operations-Nephrology Franchise
Biogen
Cambridge, MA
1w ago
$195K - $269K/yr
Associate Director – Nephrology Market Access Strategy
Biogen
Cambridge, MA
1w ago
$164K - $226K/yr
Vice President, Head of Renal Sales
Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr
Medical Science Liaison, CardioRenal - Portland, OR
AstraZeneca
Portland - OR, US
1w ago
Area Sales Manager (Florida Region)
Outset Medical
Florida Region
1w ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 516 patients
2 companies competing in this space